For instance, in vivo delivery of siRNAs targeting EGFR and BRD4 expression by peptide-modified redox responsive PEG-PEI nanoparticles have been developed for treating triple negative breast cancer cells [21], and redox-sensitive thiolated TPGS (GSH redox-sensitive thiolated vitaminE-PEG1000-succinate)-based nanoparticles have been established to target EGFR as a novel lung cancer therapy [22]. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.